Redx Pharma sees potential for RXC004 as a combination therapy
March 13, 2023 at 08:33 am EDT
Share
(via NewsDirect)
Redx Pharma PLC (AIM:REDX) chief medical officer Dr Jane Robertson speaks to Proactive's Thomas Warner after announcing that phase II data from the first group of patients being administered RXC004 for biliary tract cancer was not enough to support further development.
Robertson highlights RXC004's potential for use as a combination therapy.
Contact Details
Proactive UK Ltd
Proactive UK Ltd
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Redx Pharma Plc is a United Kingdom-based clinical-stage biotechnology company. The Company is focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. The Companyâs pipeline includes zelasudil (RXC007), zamaporvint (RXC004) and RXC008. Its lead asset, zelasudil (RXC007), a selective ROCK2 inhibitor, with potential in multiple interstitial lung diseases and cancer-associated fibrosis, is in a Phase 2 clinical program with an initial indication in idiopathic pulmonary fibrosis. RXC008 is a potential GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohnâs disease. Its oncology pipeline is led by zamaporvint (RXC004), a Porcupine inhibitor targeting Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy, and its drug discovery engine is advancing a pipeline of research programs and collaborations in both fibrotic diseases and oncology.